Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CPS1 | P31327 | 11/20 | 0.63 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531399 | 1.00 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL14016072 | 0.87 | CPS1 (0.58) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL2324673 | 0.85 | CPS1 (0.59) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL31741591 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL5196960 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL1051747 | 0.85 | CPS1 (0.63) | ALDH1A1HPGDCPS1NPC1RAB9A | |
| SCHEMBL28102429 | 0.84 | CPS1 (0.57) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL72082 | 0.83 | CPS1 (0.61) | ALDH1A1HPGDCPS1NPC1RAB9A | |
| SCHEMBL1555099 | 0.83 | CPS1 (0.61) | ALDH1A1HPGDCYP3A4MAPK1CPS1 | |
| SCHEMBL15226106 | 0.83 | CPS1 (0.61) | ALDH1A1HPGDCYP3A4MAPK1CPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110734367-B | Diphenyl ether chalcone tubulin inhibitor and preparation method and application thereof | 贵州医科大学 | 2022-06-24 | — | — | CN | claimed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025137310-A1 | CRYSTALLINE GPR40 AGONIST AND METHODS OF MAKING | KALLYOPE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-111187221-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111171000-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-115677772-B | Compound and composition for EGFR kinase inhibitor and application thereof | 浙江大学智能创新药物研究院 | 2023-08-18 | — | — | CN | disclosed |
| CN-111170999-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348468-A | CFTR modulator compounds, compositions and uses thereof | 日东制药株式会社 | 2023-06-27 | — | — | CN | disclosed |
| CN-110734367-B | Diphenyl ether chalcone tubulin inhibitor and preparation method and application thereof | 贵州医科大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-110734367-B | Diphenyl ether chalcone tubulin inhibitor and preparation method and application thereof | 贵州医科大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114502659-A | Resin composition, resin sheet, cured film, method for producing cured film, semiconductor device, organic EL display device, and display device | 东丽株式会社 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 2593/4885HPGD 4344/4885CYP3A4 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.